[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infective-endocarditis-ie\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infective-endocarditis-ie":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,76,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100633204","phase-4-anemia-therapy-in-patients-with-infective-endocarditis-100633204",false,"NCT07523646","Anemia Therapy in Patients With Infective Endocarditis","Anemia Therapy in Patients With Infective Endocarditis (POET-IRON)","POET-IRON","Inclusion Criteria:\n\n* 18 years or older\n* Confirmed bacterial endocarditis.\n* Hb ≤6.0 mmol\u002Fl\n* Stabilization criteria:\n\n  * Stable condition (patients with satisfactory clinical response to initial treatment)\n  * At least 10 days with IV administered antibiotic treatment and at least 7 days after surgery in cases of valve surgery.\n  * Transesophageal echocardiography (TEE) performed prior to randomization with no signs of abscess formation or valve abnormalities, which would require surgery.\n  * No fever for at least 48 hours prior to enrollment.No positive blood cultures within last 4 days prior to randomization.\n  * CRP \\\u003C 25 mg\u002FL OR \\> 25% reduction from peak value.\n  * Leucocytes \\\u003C15 mia.\u002FL OR \\> 25% reduction from peak value.\n\nExclusion Criteria:\n\n* Known or suspected immunocompromise (e.g., HIV infection, ongoing chemotherapy, systemic corti-costeroid treatment \\>20 mg prednisolone equivalent\u002Fday)\n* Inability to provide informed consent for participation\n* Relapsing infective endocarditis (endocarditis caused by the same microorganism within 6 months)\n* Allergy \u002F intolerance to EPO or iron therapy\n* Inability to complete a 6MWT\n* Hematological conditions, that contradicts use of IV iron therapy\n* Death prior to clinical stabilization\n* Failure to fulfill criteria of clinical stabilization","ALL","18 Years",{"count":20,"type":21},74,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Infective endocarditis (IE) is a bacterial infection of the heart valves, inserted material or surrounding struc-tures and is associated with a high morbidity and mortality. In patients with IE, anemia is considered to result from the underlying infection, prolonged sustained inflammatory response due to the often slow natural course of the disease, and coexisting comorbidities.\n\nPrevious studies have found that moderate to severe anemia is associated with a markedly higher risk of mortality in the 6-months recovery phase following treatment for IE. In many cardiac patients and patients with chronic inflammation, randomized trials have shown benefit of treatment of anemia with adjunctive therapy i.e., vitamins (vitamin B12\u002Ffolic acid), intravenous iron, and erythropoiesis stimulating agents in alleviating anemia, without increased risk of infection. Despite these findings, anemia screening and management are not addressed in current endocarditis guidelines. Thus, in patients with IE and anemia, adjunctive treatment of the anemia might be beneficial for recovery and improve outcomes.\n\nThe aim of POET-IRON is to assess the efficacy of adjunctive anemia treatment in patients with IE, using intravenous iron supplementation, erythropoietin-stimulated erythropoiesis, and dietary optimization including vitamins if necessary, and its effect on hemoglobin levels compared to standard care.\n\nThe investigators hypothesize that this intervention is safe and will increase hemoglobin concentration, thereby alleviating symptoms of anemia and improving clinical outcomes through enhanced oxygen-carrying capacity, tissue oxygenation, and functional status.",[27,28],"Infective Endocarditis (IE)","Severe Anemia",[30,31,32],"Anemia","Infective Endocarditis","Inflammation","RECRUITING","2026-05-26",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":37},"2026-05-15",{"date":41,"type":21},"2028-08",{"name":43,"class":44},"Rigshospitalet, Denmark","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100632283","the-study-tests-if-preoperative-dental-screening-is-superior-to-no-preoperative-dental-screening-in-improving-the-outcome-of-patients-undergoing-surgical-cardiac-valve-replacement-or-transcatheter-cardiac-valve-implantation-100632283","NCT07511673","The Study Tests if Preoperative Dental Screening is Superior to no Preoperative Dental Screening in Improving the Outcome of Patients Undergoing Surgical Cardiac Valve Replacement or Transcatheter Cardiac Valve Implantation.","SMILE: A Randomized Trial of Preoperative Dental Screening for the Prevention of Endocarditis, Reoperation or Death in Patients Undergoing Surgical or Transcatheter Cardiac Valve Intervention.","SMILE","Inclusion Criteria:\n\n* Age ≥18 years\n* Accepted for cardiac valve intervention\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Previous or ongoing infective endocarditis\n* Urgent surgery\n* Pain from loose tooth\u002Fteeth\n* Immunosuppressive therapy (excluding corticosteroids)\n* Inability to provide informed consent\n* Expected loss to follow-up",{"count":55,"type":21},1300,[57],"NA","This randomized, multicenter, open-label trial evaluates whether preoperative dental screening improves outcomes in patients undergoing surgical or transcatheter cardiac valve intervention. Participants are randomized 1:1 to preoperative dental screening or no screening. The primary outcome is time to first occurrence of all-cause death, redo-intervention of the index valve, or definite infective endocarditis within 2 years. The study uses registry-based follow-up to ensure complete outcome ascertainment.",[27,60],"Heart Valve Disease",[62,63,64,65,66],"Dental screening","valve intervention","endocarditis","TAVI","valve surgery",{"date":68,"type":37},"2026-05-19",{"date":70,"type":37},"2026-05-06",{"date":72,"type":21},"2036-12-01",{"name":74,"class":44},"Region Skane",5,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100614623","percutaneous-angiovac-vegetation-extraction-pave-to-remove-right-heart-vegetations-in-patients-with-infective-endocarditis-100614623","NCT07282002","Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective Endocarditis","Feasibility Protocol for Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective Endocarditis","PAVE","Inclusion Criteria:\n\n1. Subject age ≥ 18 years\n2. Subject provides a signed and dated Informed Consent Form\n3. Subject has a diagnosis of native infective endocarditis\n4. Subject has presence of bacteremia with valvular (tricuspid or pulmonic) vegetations \\> 1 cm confirmed by transesophageal echocardiogram (TEE) or transthoracic echocardiogram (TTE) with the presence of septic emboli\n5. Subject has no underlying terminal illness and subject is deemed medically eligible for interventional procedure(s) per institutional guidelines and\u002For clinical judgment\n\nExclusion Criteria:\n\n1. Subject requires debulking of vegetation on cardiac leads\n2. Subject has a prior history of ischemic\u002Fhemorrhagic stroke (within 3 months)\n3. Subject has a coagulation disorder\n4. Subject has arterial septic emboli\n5. Subject has cerebral septic embolism\n6. Subject has preoperative intubation due to ongoing hypoxemic respiratory failure\n7. Subject has fungal endocarditis\n8. Subject has atrial septal defect\n9. Subject has medically refractory right-sided heart failure secondary to valvular dysfunction (SCAI SHOCK Stage Classification D or E)\n10. Subject has planned valvular replacement\u002Frepair\n11. Subject has prosthetic valves and\u002For annular abscesses\n12. Subject has epidural abscesses\n13. Subject is pregnant or breastfeeding",{"count":85,"type":21},30,[57],"The investigation aims to demonstrate initial safety and efficacy of the AngioVac System for the removal of vegetation in the right heart in patients with infective endocarditis.",[27],[90,91],"AngioVac","Infective endocarditis (IE)","NOT_YET_RECRUITING","2026-04-17",{"date":95,"type":37},"2026-04-22",{"date":97,"type":21},"2026-04",{"date":99,"type":21},"2027-03",{"name":101,"class":102},"Angiodynamics, Inc.","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100617072","from-commensalism-to-pathogenicity-exploring-the-pathophysiology-of-bacteremia-to-better-understand-enterococcus-faecalis-infective-endocarditis-100617072","NCT07313865","From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecalis Infective Endocarditis","From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecalis Infective Endocarditisléter","BAC-ENDO","Inclusion Criteria:\n\n* Patients aged 18 years and older;\n* Capable of giving informed consent;\n* Affiliated with a social security system;\n* Hospitalized with at least one positive blood culture for Enterococcus faecalis, without an obvious clinical entry point after physical examination and initial routine investigations (BIEF group);\n* Hospitalized for another bacteremia, without an obvious clinical entry point after initial routine investigations (Control group);\n* Receiving antibiotic therapy that was started less than 48 hours ago\n\nExclusion Criteria:\n\n* Refusal to participate in the study;\n* Pregnant or breastfeeding women;\n* Individuals under guardianship, curatorship, deprived of liberty, or under judicial protection;\n* Antibiotic therapy for the current infectious episode started more than 48 hours prior to inclusion.",{"count":112,"type":21},90,[57],"Enterococci are pathobionts of the human intestinal microbiota: they colonize the gastrointestinal tract as well as the skin, urine, wounds, bile, the oral cavity and endodontic canal, and medical devices (urinary catheters, venous catheters, etc.). They are responsible for urinary, dental, bloodstream, endocardial, biliary, and gastrointestinal infections.\n\nEnterococcus faecalis is the enterococcus most frequently isolated from clinical specimens. It is the third leading cause of infective endocarditis (infection of the cardiac valves) and the leading cause of endocarditis following TAVI (transcatheter aortic valve implantation via the femoral route). E. faecalis infective endocarditis (EFIE) is severe and difficult to treat, with a particularly high relapse rate despite appropriate antibiotic therapy.\n\nCardiac valve contamination is always secondary to E. faecalis bacteremia, particularly in cases of isolated E. faecalis bacteremia (EFIB), defined by the absence of an identifiable portal of entry. Once in the bloodstream, the bacterium adheres to the valvular endothelium (healthy or damaged) through specific virulence factors, including endocarditis- and biofilm-associated pili (ebp), the collagen adhesin Ace, and aggregation substance (Agg).\n\nThe classical portals of entry for EFIE are infections of the urinary tract and the gastrointestinal tract. However, despite extensive investigations, the source of infection remains unidentified in more than 50% of cases. An imbalance of the intestinal microbiota, leading to overgrowth and subsequent translocation of E. faecalis from the digestive tract into the bloodstream, could explain the absence of an identifiable portal of entry during routine clinical and paraclinical evaluations. This plausible hypothesis remains largely unexplored to date. A better understanding of the underlying pathophysiology-particularly gut dysbiosis and the pathogen's capacity for intestinal translocation-could improve the prevention of EFIE occurrence and relapse.",[27],[117,118,119,120,121],"Enterococcus faecalis","Bacteremia","Dysbiosis","Pathophysiology","Virulence factors","2026-01-07",{"date":124,"type":37},"2026-01-09",{"date":126,"type":21},"2026-01-02",{"date":128,"type":21},"2028-12-31",{"name":130,"class":44},"University Hospital, Clermont-Ferrand"]